News
Google News
More headlines & perspectives

Tango Therapeutics and Revolution Medicines test cancer drug combo

Top news

statnews.com

Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

By Andrew Joseph
Barron's

Tango Therapeutics Stock Soars 53% After ’Unprecedented’ Data on Pancreatic Cancer Treatment

By Kit Norton
Yahoo Finance

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

BioSpace

‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response

By Gabrielle Masson

All coverage

OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

By Courtney Flaherty
Bloomberg

Tango Soars as Study Shows Its Drug Can Help Shrink Tumors

By Robert Langreth
BioWorld News

Clinical footwork pays off in Tango’s PDAC combo phase I/II

By Randy Osborne
FirstWord Pharma

Tango hopes it takes two: vopimetostat combos build on Revolution's pancreatic cancer breakthrough

TipRanks

Catanzaro Raises TNGX Price Target to $36, Reiterates Buy on Promising Vopimetostat/Daraxonrasib Data in Pancreatic Cancer

TradingView

Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36.91, Implies 83% Upside

WSJ

🔎 Under the Radar: Tango Stock Climbs on Positive Pancreatic Cancer Data

By Xavier Martinez
Benzinga

Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday

By Avi Kapoor
timothysykes.com

TNGX Stock Whipsaws As Wall Street Hikes Price Targets

By Matt Monaco
Citeline News & Insights

Tango Dances Toward Phase III With Positive Vopimetostat/Daraxonrasib Data

By Alaric Dearment
The Globe and Mail

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More

International Business Times Australia

Tango Therapeutics Shares Surge 32% on Strong Clinical Momentum in Precision Oncology

GuruFocus

Revolution Medicines (RVMD) Strengthens PDAC Position with New D

Asianet Newsable

TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’

simplywall.st

Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects

Eagle-Tribune

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% ...

Investing.com Nigeria

Why is Tango Therapeutics stock surging today? By Investing.com

By Maria Ponnezhath
Quiver Quantitative

Tango Therapeutics jumps 34% on early combo data showing 92% response rate in MTAP-deleted pancreatic cancer

MEXC

Tango Therapeutics (TNGX) Stock Surges 45% on Pancreatic Cancer Trial Data

Investor's Business Daily

Biotech Surges 45% On Eye-Popping Pancreatic Cancer Test

By Allison Gatlin
TechStock²

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

whbl.com

Tango Therapeutics’ pancreatic cancer drug combo shows promise in study

Invezz

Tango Therapeutics stock soars on promising pancreatic cancer data

Stock Titan

Experimental drug combo triggers tumor response in 92% of pancreatic patients

insidermonkey.com

Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement

Blockonomi

Tango Therapeutics (TNGX) Stock Soars 45% Following Breakthrough Pancreatic Cancer Data

Yahoo Finance

Tango data add to growing momentum for pancreatic cancer drugs

By Jonathan Gardner
TradingView

TNGX: Vopimetostat + RAS inhibitors achieved 92% ORR in 2/3L PDAC with strong safety and durability

TradingView

TNGX: Vopimetostat plus daraxonrasib showed a 92% response rate in advanced pancreatic cancer

TipRanks

Tango Therapeutics price target raised to $69 from $55 at Leerink

TradingView

TNGX: Vopimetostat plus pan-RAS inhibitors achieved 92% response in MTAP-deleted pancreatic cancer

TipRanks

Tango Therapeutics upgraded at Wolfe after ‘impressive’ vopimetsotat combo data

Benzinga

Why Is Tango Therapeutics Stock Soaring Monday?

By Vandana Singh
TipRanks

RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position

TradingView

Tango Therapeutics reports 92% ORR with vopimetostat + daraxonrasib in PDAC

Stocktwits

TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’

By Arnab Paul
Quiver Quantitative

Tango Therapeutics Reports Encouraging Initial Phase 1/2 Data on Vopimetostat and Daraxonrasib Combination for Treatment of MTAP-Deleted Pancreatic Cancer

CoinCentral

Tango Therapeutics (TNGX) Stock Surges 45% on Pancreatic Cancer Trial Data

Investing.com Canada

Tango Therapeutics stock surges 45% on pancreatic cancer data By Investing.com

By Louis Juricic
Investing.com Nigeria

Tango Therapeutics stock surges 45% on pancreatic cancer data By Investing.com

By Louis Juricic
CryptoRank

Tango Therapeutics stock soars on promising pancreatic cancer data

Investing.com Canada

Tango reports positive trial data for pancreatic cancer combo By Investing.com

TradingView

TNGX: Vopimetostat plus pan-RAS inhibitors achieved a 92% response rate in MTAP-deleted pancreatic cancer

Yahoo Finance

TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’

By Arnab Paul
GlobeNewswire

Tango Therapeutics Announces Combination of Vopimetostat

Investing.com

Wolfe Research upgrades Tango Therapeutics stock rating on trial data

Investing.com South Africa

Wolfe Research upgrades Tango Therapeutics stock rating on trial data By Investing.com

Investing.com Canada

Why is Tango Therapeutics stock surging today? By Investing.com

By Maria Ponnezhath
TradingView

TNGX: Vopimetostat plus pan-RAS inhibitors achieved 92% response and 90% 6-month PFS in MTAP-deleted pancreatic cancer

Search
Clear search
Close search
Google apps
Main menu